Bristol-Myers Forks Over $40M Upfront for Another One of Ono Pharma's Cancer Prospects
The companies will also collaborate on discovery efforts to identify additional compounds from Ono’s PGE2 receptor antagonist programs. Source: BioSpace
Kyn Therapeutics Banks $49M to Advance Cancer Immunometabolism Therapies
Investors were Atlas Venture and OrbiMed. Source: BioSpace
New Jersey Drugmaker Draws FDA Warning for Adulteration
The FDA warned sterile drug manufacturer PharmScript for adulterated products and insanitary conditions at its Somerset, New Jersey facility. Source: Drug Industry Daily
Circuit Court Upholds PTAB Ruling Invalidating Daiichi Sankyo Patents
The Federal Circuit upheld the Patent Trial and Appeal Board’s invalidation of Daiichi Sankyo’s patents for the anti-clotting drug Effient (prasugrel). Source: Drug Industry Daily
PhRMA Unveils ‘Multi-Million Dollar’ Initiative on Opioid Addiction
PhRMA announced it is partnering with the Addiction Policy Forum as part of a “multi-year, multi-million dollar” initiative to address opioid addiction. Source: Drug Industry Daily
House Panel Polls Pharmaceutical Sector on Reasons for High Drug Prices
Lawmakers once again waded into the reasons for rising drug prices, as a House panel invited a diverse group of industry representatives to weigh in on the main causes and…
J&J, Sanofi Top Bioethics International Transparency Report
Rounding out the top five companies behind J&J and Sanofi are AbbVie, Celgene and Merck. Source: BioSpace
GW Pharma, Otsuka Satvex Deal Terminated
As a result, GW has now reacquired full ownership of the development and commercialization rights to the product in the U.S. market. Source: BioSpace
Daichi Sankyo Abandons Deal With Nektar Therapeutics After Drug Tanks in Europe
Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018. Source: BioSpace
Roche Gets in on Bay Area Allakos' $100M Funding Round
The round was led by NEA and included Redmile Group, Partner Fund Management, Rock Springs Capital, LifeSci Venture Partners, Samsara BioCapital, and a large institutional investor. Source: BioSpace
- Go to the previous page
- 1
- …
- 228
- 229
- 230
- 231
- 232
- 233
- 234
- …
- 610
- Go to the next page